Trainable structure-activity relationship model for virtual screening of CYP3A4 inhibition.
A new structure-activity relationship model predicting the probability for a compound to inhibit human cytochrome P450 3A4 has been developed using data for >800 compounds from various literature sources and tested on PubChem screening data. Novel GALAS (Global, Adjusted Locally According to Similarity) modeling methodology has been used, which is a combination of baseline global QSAR model and local similarity based corrections. GALAS modeling method allows forecasting the reliability of prediction thus defining the model applicability domain. For compounds within this domain the statistical results of the final model approach the data consistency between experimental data from literature and PubChem datasets with the overall accuracy of 89%. However, the original model is applicable only for less than a half of PubChem database. Since the similarity correction procedure of GALAS modeling method allows straightforward model training, the possibility to expand the applicability domain has been investigated. Experimental data from PubChem dataset served as an example of in-house high-throughput screening data. The model successfully adapted itself to both data classified using the same and different IC₅₀ threshold compared with the training set. In addition, adjustment of the CYP3A4 inhibition model to compounds with a novel chemical scaffold has been demonstrated. The reported GALAS model is proposed as a useful tool for virtual screening of compounds for possible drug-drug interactions even prior to the actual synthesis.
Didziapetris
Remigijus
R
ACD/Labs Inc., Vilnius, Lithuania.
Dapkunas
Justas
J
Sazonovas
Andrius
A
Japertas
Pranas
P
D001185:Artificial Intelligence; D017076:Computer-Aided Design; D051544:Cytochrome P-450 CYP3A; D065692:Cytochrome P-450 CYP3A Inhibitors; D016208:Databases, Factual; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods* / Q000706:statistics & numerical data*; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D008956:Models, Chemical; D021281:Quantitative Structure-Activity Relationship; D012984:Software; D014584:User-Computer Interface
D065692:Cytochrome P-450 CYP3A Inhibitors; D004791:Enzyme Inhibitors; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human
Biochemistry. 1998 Mar 24;37(12):4137-47
9521735
Clin Pharmacokinet. 2005;44(3):279-304
15762770
Drug Metab Dispos. 2001 May;29(5):748-53
11302943
Drug Metab Dispos. 2001 Nov;29(11):1473-9
11602524
J Med Chem. 2008 Feb 28;51(4):817-34
18232648
Expert Opin Drug Metab Toxicol. 2006 Aug;2(4):629-45
16859410
Drug Metab Dispos. 2001 Mar;29(3):282-8
11181496
Bioorg Med Chem. 2009 Aug 15;17(16):5906-19
19632124
J Biol Chem. 2004 Sep 10;279(37):38091-4
15258162
J Med Chem. 2008 Oct 9;51(19):5897-900
18763755
J Chem Inf Comput Sci. 2002 May-Jun;42(3):717-28
12086534
Drug Metab Dispos. 2004 Jun;32(6):647-60
15155557
J Biomol Screen. 2005 Apr;10(3):197-205
15809315
Nat Rev Drug Discov. 2005 Oct;4(10):825-33
16224454
J Comput Aided Mol Des. 2005 Mar;19(3):189-201
16059671
SAR QSAR Environ Res. 2004 Oct-Dec;15(5-6):345-58
15669694
Drug Metab Rev. 1997 Feb-May;29(1-2):413-580
9187528
J Chem Inf Model. 2006 Sep-Oct;46(5):2125-34
16995743
SAR QSAR Environ Res. 2010 Jan 1;21(1):127-48
20373217
J Med Chem. 2007 Feb 8;50(3):501-11
17266202
Xenobiotica. 2007 Mar;37(3):246-59
17624023
Drug Metab Dispos. 2000 Dec;28(12):1440-8
11095581
Eur J Pharm Sci. 2005 Apr;24(5):451-63
15784335
Drug Discov Today. 2005 Nov 1;10(21):1443-50
16243264
Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52
10805063
J Pharmacol Exp Ther. 1999 Jul;290(1):429-38
10381809
Eur J Med Chem. 2009 Jun;44(6):2354-60
19026469
Ann N Y Acad Sci. 2000;919:26-32
11083094
Drug Metab Dispos. 2003 Sep;31(9):1108-16
12920166
J Mol Graph Model. 2008 Jun;26(8):1315-26
18328754
Drug Metab Dispos. 2003 Sep;31(9):1077-80
12920160
Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13682-7
16954191
Bioorg Med Chem. 2009 Apr 15;17(8):3130-41
19321349
Br J Pharmacol. 1998 Feb;123(4):605-10
9517377
J Comput Aided Mol Des. 2007 Oct-Nov;21(10-11):559-73
18034311
Drug Metab Dispos. 2000 Mar;28(3):360-6
10681383